The FDA on November 14, 2019 granted accelerated approval to BRUKINSA® for adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy. BRUKINSA® is a product of BeiGene, Ltd.
Bottom Ad
Advertisement
Subscribe
Top Ad
Advertisement